Michael Kagnoff is Director at GenMark Diagnostics, Inc. (GNMK). They have made 9 open-market trades across 1 company since 2015, most recently 2021-04-22.
CIK 0001632002
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
9 open-market purchases totalling $347K since 2015, never a sale. Across 9 scored buys the stock is up 12.7% at ninety days, and 9.3 points ahead of the S&P over the same stretch.
9 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| GNMK | 137,319 | $3.3M |
Shares reported on the most recent Form 4, priced at the 2021-02-19 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 67% | 56% |
| Avg Move | -2.1% | +0.5% | +12.7% |
| Alpha | +0.2% | +0.4% | +9.3% |
| Scored | 9 | 9 | 9 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GNMK | BUY | 2020-03-04 | 2020-03-05 | $4.61 | $46K | -28.9% | -23.2% | +60.2% |
| GNMK | BUY | 2018-03-01 | 2018-03-05 | $4.22 | $42K | +13.7% | +10.7% | +58.3% |
| GNMK | BUY | 2017-11-06 | 2017-11-06 | $4.13 | $83K | +23.7% | +8.8% | +29.4% |
| GNMK | BUY | 2017-09-11 | 2017-09-11 | $9.15 | $23K | +0.5% | -3.5% | -53.1% |
| GNMK | BUY | 2016-11-22 | 2016-11-22 | $11.80 | $24K | -3.3% | +4.6% | -10.1% |
| GNMK | BUY | 2016-11-14 | 2016-11-14 | $12.50 | $25K | -7.0% | -7.9% | -14.1% |
| GNMK | BUY | 2016-03-10 | 2016-03-14 | $4.90 | $12K | -1.0% | +14.3% | +73.4% |
| GNMK | BUY | 2015-10-30 | 2015-11-02 | $6.70 | $34K | -8.4% | +0.4% | -30.3% |
| GNMK | BUY | 2015-03-10 | 2015-03-11 | $11.84 | $59K | -8.4% | +0.4% | +0.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.